India’s pharmaceutical industry is at a turning point. Its heritage lies as the “pharmacy of the world” with an aggressive drive to become a leader in global innovation. This shift was further highlighted by a recent stakeholder engagement facilitated by Union Minister of Commerce and Industry Piyush Goyal. Goyal underlined India’s dedication to bolstering regulatory frameworks, encouraging innovation, and quickening growth throughout the pharmaceutical value chain at the conference. Data protection, investment flows, manufacturing scale-up, and the development of a future-ready pharmaceutical ecosystem were among the primary themes that emerged from his interactions with influential industry leaders. This increasing emphasis on policy comes at a time when the world is uncertain. Concerns regarding international trade flows have returned because of the United States proposed 100% tax on branded and patented medications. Yet the stakeholders of the Indian industry are still optimistic. India’s strength is seen in its strong export base of APIs (Active Pharmaceutical Ingredients) and generic medicines. These are largely untouched by the planned US restrictions, as observed by Sudarshan Jain of the Indian Pharmaceutical Alliance. India’s pharmaceutical exports to the US reached $2.62 billion in September 2025. This demonstrates resilience and confirms the industry’s ability to prosper even in erratic global circumstances.
A Sector Critical to India’s Economic Future
According to a report by EY Parthenon and the Organization of Pharmaceutical Producers of India (OPPI) the pharmaceutical industry is key to India’s goal of becoming a $30–35 trillion economy by 2047. The report, “Fuelling innovation, advancing equity: The power of partnerships and digital-first strategies driving Indian pharma’s global dominance,” presents a plan to move the sector away from efficiency driven by cost and toward innovation powered by science. Currently, 20% of the world’s supply of generic drugs and 60% of the world’s supply of vaccines the industry ranks third globally in terms of volume. It thereby makes an unmatched contribution to the security of global health. India’s pharmaceutical exports have almost doubled over the last ten years. It went from $15 billion in 2013–14 to $27.85 billion in FY 2023–24, edging closer to the $30 billion mark. This export performance is not just economic. It guarantees the supply of reasonably priced medications. It also supports global health systems particularly in the Global South. Pharma also has significant domestic importance. Improving public health, increasing labour productivity and lowering financial losses from disease burdens are all made possible by a robust pharmaceutical base. Pharma is one of the most important sectors in India’s growth narrative because of these consequences.
CRDMOs and GCCs: Catalysts for India’s Next Growth Curve
As per the report, three pillars are identified as India’s future pharmaceutical trajectory. First, vaccines and generics, second Organizations for Contract Research, Development, and Manufacturing (CRDMOs/CDMOs) and last, Centers of Global Capability (GCCs). As pharmaceutical companies outsource complicated Research and Development (R&D) and manufacturing tasks, CRDMOs are becoming increasingly well-known worldwide. With a 9% compound annual growth rate, the global CRDMO market is expected to reach $303 billion by 2028. India is becoming a significant participant in this market. India is investing more in advanced chemistry, biology, analytics and digital infrastructure. Indian CRDMOs are helping India move from being a low-cost manufacturing hub to an integrated partner in state-of-the-art drug innovation. This change signifies a fundamental metamorphosis: India is now contributing significantly to scientific research that determines the direction of global treatments rather than merely manufacturing pharmaceuticals.
On the other hand, India’s deep talent pool, digital capabilities and cost advantages have made it a preferred destination for Global Capability Centres (GCCs). Nearly half of the world’s leading life sciences companies have set up GCCs in India. These centres now drive enterprise-wide innovation rather than merely offering back-end support. With advanced work in AI, machine learning, bioinformatics, and automation, GCCs are transforming processes. These are target identification, trial optimization and pharma-vigilance. They signal India’s emergence not just as a production centre, but as a global knowledge hub.
Critical Gaps and Industry Concerns
Despite its advantages, the industry continues to encounter difficulties in generic drug price decline, endangering long-term viability, low R&D spending, much less than international standards and innovation cycles are slowed by regulatory obstacles. Lack of expertise in cutting-edge treatments Industry CXOs interviewed for the EY-OPPI report all agreed that India has to move from “scale to science.” They emphasized that predictability leads to partnerships. Further highlighting the necessity of more robust intellectual property frameworks, clear regulations and data protection reforms to draw in early-phase research.
Conclusion: A Defining Moment for India’s Pharma Future
India’s pharmaceutical industry has long benefited the world by producing large quantities of affordable medications. Building a future-ready and innovation-led ecosystem that boosts India’s competitiveness is a must. It deepens international relationships and continues to provide easily accessible healthcare solutions. This should be the clear objective, as Minister Piyush Goyal emphasised. India has the potential to become not only the world’s pharmacy but also one of its most significant leaders in the life sciences with the correct legislative push and industrial dedication.
Clear Cut Health Desk
New Delhi, UPDATED: Nov 30, 2025 09:20 IST
Written By: Nidhi Chandrikapure
